Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jul 26, 2021; 13(7): 670-684
Published online Jul 26, 2021. doi: 10.4252/wjsc.v13.i7.670
Published online Jul 26, 2021. doi: 10.4252/wjsc.v13.i7.670
Epigenetic modulators for brain cancer stem cells: Implications for anticancer treatment
Luana Abballe, Evelina Miele, Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome 00165, Italy
Author contributions: Abballe L collected the data and wrote the paper; Miele E contributed to the conception and design and was responsible for review supervision; both authors read and approved the final version of the manuscript.
Supported by Italian Ministry of Health , Ricerca Finalizzata, No. GR-2018-12367328 (to Miele E).
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Evelina Miele, MD, PhD, Medical Assistant, Postdoc, Research Scientist, Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Piazza di Sant'Onofrio, 4, Rome 00165, Italy. evelina.miele@opbg.net
Received: March 13, 2021
Peer-review started: March 13, 2021
First decision: April 6, 2021
Revised: April 26, 2021
Accepted: June 22, 2021
Article in press: June 22, 2021
Published online: July 26, 2021
Peer-review started: March 13, 2021
First decision: April 6, 2021
Revised: April 26, 2021
Accepted: June 22, 2021
Article in press: June 22, 2021
Published online: July 26, 2021
Core Tip
Core Tip: Cancer stem cells (CSCs) are characterized by an altered epigenome that contributes to treatment failure and tumor relapse. Physicians are looking for new therapeutic approaches to target specifically CSCs in cancers. In this review, we summarize literature data about epigenetic markers in brain CSCs and shed light on new epigenetic therapies.